Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 5/20 | 0.41 |
| ▸ | CA1 | P00915 | 5/20 | 0.41 |
| ▸ | CA2 | P00918 | 5/20 | 0.41 |
| ▸ | CA9 | Q16790 | 5/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | TYMP | P19971 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | NOS1 | P29475 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4262422 | 0.74 | — | — | |
| SCHEMBL8975255 | 0.74 | — | — | |
| SCHEMBL6131634 | 0.74 | — | — | |
| SCHEMBL1979557 | 0.74 | — | — | |
| SCHEMBL3955047 | 0.74 | — | — | |
| SCHEMBL6236180 | 0.74 | — | — | |
| SCHEMBL17635577 | 0.74 | — | — | |
| SCHEMBL63265 | 0.74 | — | — | |
| SCHEMBL3607267 | 0.74 | — | — | |
| SCHEMBL7555585 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 103 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117658991-A | Abnormal-shape difunctional crosslinking agent and preparation method and application thereof | 南昌大学 | 2024-03-08 | — | — | CN | claimed |
| US-9746300-B1 | Voltage induced porosity in insensitive munition | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE ARMY (US) | 2017-08-29 | — | — | US | claimed |
| JP-2012500183-A | — | — | 2012-01-05 | — | — | JP | claimed |
| EP-1650211-B1 | Process for preparing imidazopyran derivatives | DAISO CO LTD (JP) | 2011-09-14 | — | — | EP | claimed |
| EP-2323990-A1 | METHODS FOR THE PRODUCTION OF 2-HALO-4-NITROIMIDAZOLE AND INTERMEDIATES THEREOF | Dynamit Nobel GmbH Explosivstoff- und Systemtechnik (DE) | 2011-05-25 | — | — | EP | claimed |
| WO-2010021409-A1 | METHODS FOR THE PRODUCTION OF 2-HALO-4-NITROIMIDAZOLE AND INTERMEDIATES THEREOF | DYNAMIT NOBEL GMBH EXPLOSIVSTOFF - UND SYSTEMTECHNIK (DE) | 2010-02-25 | — | — | WO | claimed |
| EP-2027079-A2 | GAS GENERATION WITH COPPER COMPLEXED IMIDAZOLE AND DERIVATIVES | Autoliv ASP, INC. (US) | 2009-02-25 | — | — | EP | claimed |
| US-7470337-B2 | Gas generation with copper complexed imidazole and derivatives | AUTOLIV ASP, INC. (US) | 2008-12-30 | — | — | US | claimed |
| WO-2008051274-A2 | GAS GENERATION WITH COPPER COMPLEXED IMIDAZOLE AND DERIVATIVES | AUTOLIV ASP, INC. (US) | 2008-05-02 | — | — | WO | claimed |
| US-20070240797-A1 | Gas generation with copper complexed imidazole and derivatives | AUTOLIV ASP, INC. | 2007-10-18 | — | — | US | claimed |
| US-20040024223-A1 | Process for the synthesis and recovery of nitramines | NORTHROP GRUMMAN SYSTEMS CORPORATION | 2004-02-05 | — | — | US | claimed |
| US-6603018-B2 | Rockets; propullants | ALLIANT TECHSYSTEMS INC. | 2003-08-05 | — | — | US | claimed |
| US-20020156291-A1 | Process for the synthesis and recovery of nitramines | ORBITAL ATK, INC. (F/K/A ALLIANT TECHSYSTEMS INC.) | 2002-10-24 | — | — | US | claimed |
| WO-2002060881-A1 | PROCESS FOR THE SYNTHESIS AND RECOVERY OF NITRAMINES | ALLIANT TECHSYSTEMS INC. (US) | 2002-08-08 | — | — | WO | claimed |
| US-5387297-A | 2,4-dinitroimidazole- a less sensitive explosive and propellant made by thermal rearrangement of molten 1,4 dinitroimidazole | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE ARMY (US) | 1995-02-07 | — | — | US | claimed |
| EP-0293742-B1 | PROCESS FOR THE PRODUCTION OF 4-NITRO-5-IMIDAZOLYLETHERS AND -THIOETHERS | BASF Aktiengesellschaft (DE) | 1992-07-22 | — | — | EP | claimed |
| US-4900825-A | REACTING DINITROIMIDAZOLES WITH ALCOHOLS OR MERCAPTANS | BASF AKTIENGSELLSCHAFT (DE) | 1990-02-13 | — | — | US | claimed |
| EP-0348803-A1 | Process for the preparation of 5-cyano-4-nitroimidazoles | BASF Aktiengesellschaft (DE) | 1990-01-03 | — | — | EP | claimed |
| EP-0337255-A1 | Process for the preparation of 4-nitro-5-aminoimidazoles | BASF Aktiengesellschaft (DE) | 1989-10-18 | — | — | EP | claimed |
| EP-0293742-A1 | Process for the production of 4-nitro-5-imidazolylethers and -thioethers | BASF Aktiengesellschaft (DE) | 1988-12-07 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020156291-A1 | Process for the synthesis and recovery of nitramines | NNMT, PNMT, NISCH | CA12 2107/4885CA1 1042/4885CA2 1107/4885 |
| US-20040024223-A1 | Process for the synthesis and recovery of nitramines | NNMT, NCL, PNMT | CA12 1912/4885CA1 982/4885CA2 1176/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.